Anika Therapeutics Inc. (ANIK) Earnings Call Analysis

NASDAQ · Healthcare · Medical Instruments & Supplies

20/25

Growth 5 Margin 4 Expansion 5 Platform 2 Financial 4

latest quarter score

Earnings Reports

20
ANIK Q2 2026: Gross Margin Climbs to 65% as Lean Transformation Drives Structural Profitability
July 29, 2026
17
Anika (ANIK) Q1 2026: Commercial Channel Up 12% as Integrity Adoption Accelerates
April 29, 2026
16
Anika (ANIK) Q4 2025: Commercial Channel Grows 22% as Integrity Adoption Doubles, Offsetting OEM Drag
February 27, 2026
11
Anika (ANIK) Q3 2025: Commercial Channel Jumps 22% as Integrity Platform Doubles Penetration
November 05, 2025
9
Anika (ANIK) Q2 2025: Integrity Drives 41% Regenerative Growth as Hyalofast Timeline Extends
July 30, 2025
13
Anika (ANIK) Q1 2025: Commercial Channel Grows 18% as OEM Pricing Headwinds Cut Margins
July 06, 2025
13
Anika Therapeutics (ANIK) Q4 2024: 40% Sequential Growth in Integrity Implant System Drives Commercial Channel Expansion
March 12, 2025
Anika Therapeutics (ANIK) Q1 2024: Cost Actions Unlock $10M Savings, Margin Improvement Drives EBITDA Turnaround
August 08, 2024
Anika (ANIK) Q1 2024: Cost Actions Unlock $10M Savings, Paving Way for 75% EBITDA Growth
May 08, 2024
Anika (ANIK) Q4 2023: $10M Cost Cuts and 75% EBITDA Jump Signal Accelerated Profitability Pivot
March 13, 2024
22
Anika Therapeutics (ANIK) Q3 2023: Joint Preservation Jumps 14% as New Launches Fuel Growth Trajectory
November 02, 2023
Anika (ANIK) Q2 2023: OA Pain Management Soars 22% as Pipeline Accelerates $3B Market Reach
August 08, 2023
Anika (ANIK) Q1 2023: Joint Preservation Grows 11%, Portfolio Expansion Drives Long-Term Leverage
May 09, 2023
Anika (ANIK) Q4 2022: Joint Preservation Revenue Climbs 8% as Product Launches Drive Inflection
March 06, 2023

Browse all companies